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Low eukaryotic viral richness 
is associated with faecal 
microbiota transplantation 
success in patients with UC
We read with interest the recent Gut study 
by Zuo and colleagues showing that a good 
outcome of faecal microbiota transplanta-
tion (FMT) in Clostridium difficile infection 
(CDI) was associated with bacteriophage 
transfer.1 FMT is an established treatment 
to restore a balance in disturbed intestinal 
microbiotas of patients with CDI,2 3 and 
recent multicentre randomised, double-
blind, placebo-controlled trials showed its 
effectiveness in inducing clinical and endo-
scopic remission in patients with UC.4 We 
examined the gut virome dynamics of nine 
patients with UC who were undergoing FMT 
(64 patient and 8 healthy donor samples).5 
Two patients with UC achieved long-lasting 
complete remission with mucosal healing 
(>2 years; figure 1: patient 1 and 3), and 
one patient reported temporary remission 
for 6 weeks (figure 1; patient 4).5 The 
remaining six patients did not respond to 
treatment. Using the NetoVIR protocol,6 
we analysed the faecal virome (both RNA/
DNA genomes of phages and eukary-
otic viruses) using tailored bioinformatics 
approaches (see online supplementary 
figure 1 Overview of the sample collection from patients and donors and their respective 
remission periods. For the partial responder (patient 4), samples from the remission period were 
considered as responder in the analyses. Patient 3 vomited after the first FMT, leading to bilateral 
aspiration and bilateral pneumonia for which the patient was treated for 14 days with broad-
spectrum antibiotics. On patient’s request, a second FMT was administered 8 weeks later, and the 
patient has been in clinical remission ever since. FMT, faecal microbiota transplantation.
figure 2 (A) Phageome and (B) eukaryotic virome richness comparisons between: (1) healthy 
donor and patients; (2) responders and non-responders at baseline and (3) donors of responders 
and non-responders at baseline.
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data). Irrespective of their outcome, no 
statistical differences were observed in 
phageome richness between patients with 
UC and healthy donors (figure 2A) at any 
time point, in contrast with the findings 
of Norman and colleagues, who observed 
a lower DNA phage richness in healthy 
controls compared with IBD patients.7 
However, for the eukaryotic virome, 
healthy donors presented a significantly 
lower richness than patients at baseline 
(figure 2B, p value=0.033). Furthermore, 
before FMT, responders already presented 
a significantly lower eukaryotic viral rich-
ness than non-responders (figure 2B, 
p=0.047). These two observations suggest 
that eukaryotic virome richness is a poten-
tial novel diagnostic marker for UC and 
UC FMT response. In contrast with the 
observations for bacteria,5 the richness of 
donor viromes was not associated with the 
outcome of therapy (figure 2B, p=0.177). 
Overall, the most abundant eukaryotic viral 
families found were Anelloviridae, Circovi-
ridae, Picobirnaviridae and Virgaviridae (see 
online supplementary data).
To investigate donor virome retention, 
we adapted the bacteriome concept of trans-
ferred phylotypes8 and defined a transferred 
viral operational taxonomic unit (OTU) as 
being present in the donor sample and intro-
duced or increased in the patient samples 
post-FMT. While we did not observe any 
transferred eukaryotic viral families, only 
the full responder (patient 1) presented nine 
transferred phage OTUs.
Our results highlight, for the first time, 
the importance of the eukaryotic virome in 
UC. It is clear that eukaryotic viruses and 
phages have different ways of affecting the 
human host9 and our findings now highlight 
the importance of analysing the phageome 
and eukaryotic virome separately. In our 
study, FMT responders already presented 
a significant lower eukaryotic virome 
richness than non-responders at base-
line (figure 2A), which is a feature of the 
healthy donors. Although this study was 
not designed for diagnostic biomarker 
discovery and sample size is low, these 
results might lead towards a potential diag-
nostic marker for UC to increase treatment 
success. The published bacteriome analyses 
on the same cohort showed that responders 
had significantly higher transferred bacte-
rial phylotypes.5 Moreover, only the full 
responder presented transferred phage 
OTUs, suggesting phage transfer concom-
itant with their respective hosts.
In summary, our study shows that virome 
prescreening of patients with UC prior to 
FMT might be a valuable biomarker for 
response prediction. Further validation 
in a bigger cohort will enable building a 
predictive model for response to increase 
FMT success in UC. These results empha-
sise that our understanding of human gut 
viromes and their role in chronic disease is 
still limited, and further studies are urgently 
needed to understand their role in UC 
aetiology. The fact that the phageome was 
successfully associated with FMT in CDI,1 
while eukaryotic viruses seem more relevant 
in UC, suggests that virome interactions are 
disease specific and FMT guidelines should 
be tailored to the pathology at hand.
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